All Oncology News

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

Exposure to pollutants, such as pesticides and whildfires, could decrease brain and behavioral function in children, particularly in childhood cancer survivors.

An HMR risk signature predicted outcomes in multiple myeloma, linked with genomic instability, immune microenvironment, and drug sensitivity.

Neoadjuvant palbociclib plus endocrine therapy did not improve PEPI scores in operable hormone receptor–positive breast cancer.

The NDA seeking approval of KN026 plus chemotherapy in HER2-positive gastric or GEJ cancer has been accepted for review in China.

In an OncLive Peer Exchange, a panel of lung cancer experts discussed updated data in EGFR-mutated NSCLC from WCLC 2025.

T-DXd demonstrated durable systemic and intracranial responses in patients with HER2-positive, -low, and -zero breast cancer brain metastases.

New technology and facility expansions at the Mayo Clinic will soon enable it to treat nearly 75% more patients each year with even more precise and effective therapies.

Ligufalimab has been granted orphan drug designation by the FDA for the treatment of patients with AML.

The novel ADC CRB-701 was granted FDA fast track designation for the treatment of patients with recurrent or metastatic pretreated HNSCC.

The combination of metformin, letrozole, and abemaciclib was safe and active in patients with ER-positive recurrent endometrial cancer.

The FDA approval of belzutifan in patients with pheochromocytoma or paraganglioma is a testament to the power of drug discovery in rare tumor subsets.

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Neoadjuvant tislelizumab plus chemotherapy yielded responses in locally advanced cervical cancer.

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

A new drug application for nadofaragene firadenovec in BCG-unresponsive bladder cancer has been accepted for review in Japan.

Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.

The Idylla CDx MSI Test will soon be available as a companion diagnostic for identifying patients with MSI-H CRC eligible for treatment with nivolumab.

Raludotatug deruxtecan earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab treatment.

BTK inhibitors were associated with lower health care resource utilization vs other regimens in mantle cell lymphoma.

IDE397 plus sacituzumab govitecan shows preliminary efficacy in MTAP-deletion urothelial cancer.

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.

Trastuzumab pamirtecan improved progression-free survival in HER2-positive advanced breast cancer after prior trastuzumab and taxane-based chemotherapy.

Vanda Salutari, MD, discusses the efficacy of first-line rucaparib maintenance therapy in patients with HRD-negative high-grade, advanced ovarian cancer.

Huntsman Cancer Institute has been listed 10th among the top 75 cancer care hospitals in the US.